Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Part A: -To evaluate the steady state pharmacokinetics (PK) of tenofovir alafenamide (TAF) and confirm the dose of TAF 25 mg tablet given once daily in treatment-naïve and treatment-experienced adolescent subjects (aged 12 to < 18 years) with chronic hepatitis B (CHB). Part B: To evaluate the safety, tolerability, and antiviral activity (HBV DNA < 20 IU/mL) of TAF 25 mg once daily versus placebo through Week 24 in treatment-naive and treatment-experienced adolescent subjects with CHB
Inclusion criteria
- Chronic hepatitis B